Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment

Blood

Volumn 101, Issue 10, 2003, Pages 3862-3867

  Relling, Mary V ^a   Boyett, James M ^b   Blanco, Javier G ^b   Raimondi, Susana ^b   Behm, Frederick G ^b   Sandlund, John T ^b   Rivera, Gaston K ^b   Kun, Larry E ^b   Evans, William E ^b   Pui, Ching Hon ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SKULL IRRADIATION; STANDARDIZATION; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; INCIDENCE; INFANT; MYELODYSPLASTIC SYNDROME; PRESCHOOL CHILD; SECOND CANCER;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PLACEBOS;

EID: 0037588995     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2405     Document Type: Article

References (64)

1. Winick NJ, McKenna RW, Shuster JJ, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol. 1993;11:209-217.
2. Pui C-H, Ribeiro R, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphocytic leukemia. N Engl J Med. 1991;325:1682-1687.
3. Thomsen J, Schroder H, Kristinsson J, et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells. Cancer. 1999;86:1080-1086.
4. Pui C-H, Relling MV. Topoisomerase II inhibitor-related acute myeloid leukemia. Br J Haematol. 2000;109:13-23.
5. Loning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood. 2000;95:2770-2775.
6. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 1999;17:569-577.
7. Pui CH, Relling MV, Rivera GK, et al. Epipodophyllotoxin-related acute myeloid leukemia-a study of 35 cases. Leukemia. 1995;9:1680-1684.
8. Haupt R, Fears TR, Heise A, et al. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations. Int J Cancer. 1997;71:9-13.
9. Relling MV, Yanishevski Y, Nemec J, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia. 1998;12:346-352.
10. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A. 1998;95:13176-13181.
11. Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 1999;94:803-807.
12. Blanco JG, Edick MJ, Hancock ML, et al. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics. 2002;12: 605-611.
13. Travis LB, Andersson M, Gospodarowicz M, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst. 2000;92:1165-1171.
14. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13:335-342.
15. Pui C-H, Relling MV, Behm FG, et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia. 1995;9:1680-1684.
16. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med. 1992; 327:99-106.
17. Metcalf D. The colony stimulating factors: discovery, development, and clinical applications. Cancer. 1990;65:2185-2195.
18. Kojima S, Tsuchida M, Matsuyama T. Myelodysplasia and leukemia after treatment of aplastic anemia with G-CSF. N Engl J Med. 1992;326: 1294-1295.
19. Soutar RL. Acute myeloblastic leukemia and recombinant granulocyte colony stimulating factor. BMJ. 1991;303:123-124.
20. Ozer H, Miller LL, Anderson JR, et al. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 1994;12:2471-2508.
21. Geller RB. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol. 1996;14:1371-1382.
22. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines: American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000;18:3558-3585.
23. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia: The International Acute Myeloid Leukemia Study Group. Blood. 1997;90:4710-4718.
24. Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood. 1998;91:3607-3615.
25. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia: AML Cooperative Study Group. N Engl J Med. 1995; 332:1678-1683.
26. Gisselbrecht C, Haioun C, Lepage E, et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration: Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma. 1997;25: 289-300.
27. Thomas X, Fenaux P, Dombret H, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia. 1999;13:1214-1220.
28. Witz F, Sadoun A, Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients: Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1998; 91:2722-2730.
29. Locasciulli A, Arcese W, Locatelli F, Di Bona E, Bacigalupo A. Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy: Italian Aplastic Anaemia Study Group. Lancet. 2001;357:43-44.
30. Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood. 1997;90:1009-1013.
31. Freedman MH, Bonilla MA, Fier C, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood. 2000;96:429-436.
32. Ohara A, Kojima S, Okamura J, et al. Evolution of myelodysplastic syndrome and acute myelogenous leukaemia in children with hepatitis-associated aplastic anaemia. Br J Haematol. 2002;116: 151-154.
33. Bernard T, Gale RE, Evans JP, Linch DC. Mutations of the granulocyte-colony stimulating factor receptor in patients with severe congenital neutropenia are not required for transformation to acute myeloid leukaemia and may be a bystander phenomenon. Br J Haematol. 1998;101:141-149.
34. Tidow N, Pilz C, Teichmann B, et al. Clinical relevance of point mutations in the cytoplasmic domain of the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Blood. 1997;89:2369-2375.
35. Imashuku S, Hibi S, Nakajima F, et al. A review of 125 cases to determine the risk of myelodysplasia and leukemia in pediatric neutropenic patients after treatment with recombinant human granulocyte colony-stimulating factor. Blood. 1994;84: 2380-2381.
36. Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med. 1997;336:1781-1787.
37. Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
38. Dervieux T, Brenner T, Hon YY, et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood. 2002:100;1240-1247.
39. Stute N, Santana VM, Rodman JH, et al. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood. 1992;79:2849-2854.
40. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons, 1980.
41. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals Stat. 1988;16:1141-1154.
42. Dong F, Brynes RK, Tidow N, et al. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995;333:487-493.
43. Pui C-H, Behm FG, Raimondi SC, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989; 321:136-142.
44. Felix CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol. 2001;36:525-535.
45. Kushner BH, Heller G, Cheung NK, et al. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. J Clin Oncol. 1998;16:3016-3020.
46. Micallef IN, Lillington DM, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000;18:947-955.
47. Thirman MJ, Larson RA. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am. 1996; 10:293-320.
48. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995;86:3542-3552.
49. Harousseau JL, Witz B, Lioure B, et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol. 2000;18:780-787.
50. Moore JO, Dodge RK, Amrein PC, et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with azindinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood. 1997; 89:780-788.
51. Jeha S, Chan KW, Aprikyan AG, et al. Spontaneous remission of granulocyte colony-stimulating factor-associated leukemia in a child with severe congenital neutropenia. Blood. 2000;96:3647-3649.
52. Laver JH, Barredo JC, Amylon M, et al. Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report. Leukemia. 2000;14:369-373.
53. Inukai T, Sugita K, Iijima K, et al. Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF. Leukemia. 1998;12:382-389.
54. Top 200 drugs by WAC for hospitals in 2001. Drug Topics [serial online at www.drugtopics. com]. February 18, 2002;4:hse14.
55. Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines: Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol. 1999;17:3676-3681.
56. Rodriguez-Galindo C, Poquette CA, Marina NM, et al. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. J Pediatr Hematol Oncol. 2000;22:321-329.
57. Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol. 1999;17:3374-3388.
58. Brodsky RA, Bedi A, Jones RJ. Are growth factors leukemogenic? Leukemia. 1996;10:175-177.
59. Heyn R, Khan F, Ensign LG, et al. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report. Med Pediatr Oncol. 1994;23: 99-106.
60. Sugita K, Furukawa T, Tsuchida M, et al. High frequency of etoposide-related secondary leukemia in children with non-Hodgkin's lymphoma. Am J Pediatr Hematol Oncol. 1993;15:99-104.
61. Blanco JG, Dervieux T, Edick MJ, et al. Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2001;98:10338-10343.
62. Gundestrup M, Klarskov AM, Sveinbjornsdottir E, et al. Cytogenetics of myelodysplasia and acute myeloid leukaemia in aircrew and people treated with radiotherapy. Lancet. 2000;356:2158.
63. Deininger MW, Bose S, Gora-Tybor J, et al. Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. Cancer Res. 1998;58:421-425.
64. Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med. 1997;336:1776-1780.